MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. - Wikidata - awgldk - TriplyDB

MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.

MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.

http://www.wikidata.org/entity/Q36508191

about

Clinical Development of the E75 Vaccine in Breast Cancer The Promise of Preventive Cancer Vaccines MUC1 Predicts Colorectal Cancer Metastasis: A Systematic Review and Meta-Analysis of Case Controlled Studies Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications Cancer vaccines The emerging role of immunotherapy in colorectal cancer Cancer chemoprevention: Much has been done, but there is still much to do. State of the art and possible new approaches Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients.Optimized construction of MUC1-VNTRn DNA vaccine and its anti-pancreatic cancer efficacy Colorectal cancer immunotherapy.HCA519/TPX2: a potential T-cell tumor-associated antigen for human hepatocellular carcinoma MUC1: a multifaceted oncoprotein with a key role in cancer progression.Prognostic significance of mucin expression in urothelial bladder cancer.Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic.Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008 The antigenic repertoire of premalignant and high-risk lesions.Regulatory considerations for clinical development of cancer vaccines MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice.CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function The FDA guidance on therapeutic cancer vaccines: the need for revision to include preventive cancer vaccines or for a new guidance dedicated to them Molecular basis of antibody binding to mucin glycopeptides in lung cancer Cancer immunoprevention.Combined adjuvants of poly(I:C) plus LAG-3-Ig improve antitumor effects of tumor-specific T cells, preventing their exhaustion.Transforming Cancer Prevention through Precision Medicine and Immune-oncology.Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential Dendritic cells in cancer immunotherapy clinical trials: are we making progress?Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes.Global Inhibition of DC Priming Capacity in the Spleen of Self-Antigen Vaccinated Mice Requires IL-10.Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen.Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer.Primary 4T1 tumor resection provides critical "window of opportunity" for immunotherapy.Personalized immune-interception of cancer and the battle of two adaptive systems--when is the time right?The adenocarcinoma cell surface mucin receptor for alpha-fetoprotein: is the same receptor present on circulating monocytes and macrophages? A commentary.Cancer immunoprevention--the next frontier.Designing effective vaccines for colorectal cancer.Impact of the immune system and immunotherapy in colorectal cancer.Update on Mucin-1 immunotherapy in cancer: a clinical perspective.

P2860

Q26745440-14D1AAE7-6CF8-421D-BC98-42802F507A0A Q26783742-62FF8951-D481-444B-A61D-52252FD01E67 Q26787178-59061856-887A-4E4F-8C19-540EC9FE370D Q26799126-E911A39B-35E4-477D-896B-EC0DCC9B2AD1 Q27014189-9D5DA8BA-67A7-428C-9E9D-A18FC99170D9 Q27024438-D31A8ACC-007C-4B91-8E59-125F884C24B3 Q28067898-F9901E88-91D8-4257-8315-5028C77FC984 Q28080472-7EC514DB-5932-43B2-9905-B7286A654ED7 Q28082487-9D3ACB88-959D-4738-9773-2BA489A6D45F Q28084627-4C7BCCE9-472F-48B4-BE9A-453F40B5EDCD Q33564156-212FAD1D-26E7-42BD-B0A3-728F37AA8007 Q33599115-BDE66C26-9637-47F4-9A3E-57B347147050 Q33701465-61EDB3B2-7E2F-489A-95DF-C9635C5616ED Q33779140-94D77C7F-3B70-445F-A143-300C4399C5BF Q33880143-9944A3B0-D75F-421E-9C10-0CD0A3335390 Q34121441-B663A745-0435-42D9-86BC-3F8031688B8B Q34180316-9972CDB1-2DF0-4434-96BA-C21667C8263E Q34306503-D9CBC279-F49E-49C2-A7EE-C5E24435138C Q35251460-97D565FA-3775-4808-A204-B2CB95263448 Q35886454-677894C0-9CD6-413E-B013-BCCDA6F2EE53 Q35898801-0E84DB79-D103-42D1-8060-A1EAC4D3CE08 Q36204706-88DAC342-B0F2-41BD-B8B2-8C7CB1EB797F Q36248790-6B187AA6-A3B2-490B-93C7-F7D75ECA8F31 Q36498123-DC571E96-A672-4633-9363-641D097442CF Q36723234-0373A8BF-C2B0-4E9D-8D7A-2D5EEB8C9E3C Q36801213-718EA873-9A02-4FF0-99CD-B02227FC47EA Q37114360-535D316E-1B6B-4831-941C-628126B7914A Q37193096-F0E48E79-51A6-4066-900C-C9F202316418 Q37389096-64FADB51-9E23-4109-98A8-087B6EF586F8 Q37544847-DF9B3A47-506A-46C7-91E7-0DCB266F5E0F Q37587225-C662B74C-9EAA-44EB-B9F1-07C170CD953F Q37589407-DCA56F13-75CD-4278-846A-608052B234D3 Q37622949-BD94C1A1-5E68-4BC6-ADE2-1E708C55ECAF Q37625349-8803DB12-B34C-4110-9727-1753C4C38FB2 Q38076107-1319E6DB-EF19-4B08-A8A6-121D8EE0ABF0 Q38219296-67F6F3B8-1BAF-4A75-B72C-8811569EB33A Q38253260-0D48F716-690B-4B7D-82B4-953BD4D8E031 Q38260051-4BC46999-A28A-4131-8786-16FB89F79BC3 Q38398877-95AA8D0E-9F3C-4E0E-83D6-966A166B1DF2 Q38603410-C63F5BB9-36E6-497D-88D8-47384CF6424E

P2860

MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.

http://www.wikidata.org/entity/Q36508191

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

MUC1 vaccine for individuals w ...... oprevention feasibility study.

@ast

MUC1 vaccine for individuals w ...... oprevention feasibility study.

@en

type

label

MUC1 vaccine for individuals w ...... oprevention feasibility study.

@ast

MUC1 vaccine for individuals w ...... oprevention feasibility study.

@en

prefLabel

MUC1 vaccine for individuals w ...... oprevention feasibility study.

@ast

MUC1 vaccine for individuals w ...... oprevention feasibility study.

@en

P1433

Q36508191-94608D65-34FF-4257-B9B8-7A38C412F4D5

P1476

Q36508191-D36C268A-6DEA-4B4D-8EC2-A1DC32C9E638

P2093

Q36508191-0BF6CB10-519D-40C4-9BD3-7CF4BFFD4192

Q36508191-679B0D74-9F73-4286-9DCF-AD6DB0AA11ED

Q36508191-834A768D-D4BF-4F9A-AE61-2BB40F9F4E5E

Q36508191-AB610C83-6E20-494C-9A9A-43BE70B9F2EF

Q36508191-AF66718F-F88C-491A-ACA1-9A88B192E7D3

Q36508191-DBC301C5-22CC-44F9-AB16-ECB57D5E4217

Q36508191-F4033C6F-8A4D-4A4A-B20D-1A6F13EABBB1

Q36508191-FF2209E0-8606-423C-A188-79FA81098851

P2860

Q36508191-0151F8E3-7FD3-472F-A1A7-A145A26FFB3B

Q36508191-01B7E26A-7D88-419F-BA00-B0F55B665370

Q36508191-092BCF84-9BA0-4E35-80F9-1B288CD2F90B

Q36508191-1482B408-336C-4BF1-AB34-355A7B8F22E6

Q36508191-1992A5C7-7FC5-4B0E-9C7F-34705F932F47

Q36508191-1C128B8D-1FE6-41AE-A344-F2B38CAE6ACF

Q36508191-1FB80CF0-3CCB-471D-AEDE-2B429FA9A1A2

Q36508191-223633C5-6BC5-45D7-811E-0CE6F37E5315

Q36508191-243257D5-65B1-44A2-8B1C-FB96FBE4F047

Q36508191-251658B2-0955-4025-A5E7-3A1088864E94

P304

Q36508191-7F27B65C-3919-431E-9553-47BB42E620A5

P31

Q36508191-9C766265-DDCB-4FC7-BB6E-146425DAD313

P356

Q36508191-ECFE8C15-5BDB-47E3-8DEE-8D33CD5E5F6E

P433

Q36508191-7BEFF467-6255-4D5D-B086-1501631F25F5

P478

Q36508191-5325952B-ACC6-49DE-BF9B-B890D901398C

P577

Q36508191-21C28130-6A25-4BBC-B3F1-D4EF7B030B77

P698

Q36508191-D0B48FC2-68F3-4161-977C-A8BED61D34C8

P932

Q36508191-28D87FFD-148F-473C-8278-A2403077CCC5

P356

1940-6207.CAPR-12-0275

P1433

Cancer Prevention Research

P1476

MUC1 vaccine for individuals w ...... oprevention feasibility study.

@en

P2093

Andres M Salazar

http://www.w3.org/2001/XMLSchema#string

Douglas M Potter

http://www.w3.org/2001/XMLSchema#string

John R McKolanis

http://www.w3.org/2001/XMLSchema#string

Kazi Islam

http://www.w3.org/2001/XMLSchema#string

Lynda A Dzubinski

http://www.w3.org/2001/XMLSchema#string

Olivera J Finn

http://www.w3.org/2001/XMLSchema#string

Robert E Schoen

http://www.w3.org/2001/XMLSchema#string

Takashi Kimura

http://www.w3.org/2001/XMLSchema#string

P2860

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Myeloid-derived suppressor cells as regulators of the immune system

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

Cell surface-associated mucins in signal transduction

Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology

Myeloid suppressor cells induced by hepatitis C virus suppress T-cell responses through the production of reactive oxygen species.

Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function.

Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses.

Mumps and ovarian cancer: modern interpretation of an historic association.

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

P304

18-26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1940-6207.CAPR-12-0275

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23248097

http://www.w3.org/2001/XMLSchema#string

P932

3536916

http://www.w3.org/2001/XMLSchema#string